In order to characterize the DiSTRES regulation system in the context of a prostate cancer therapeutic, we first subcloned the FasL-GFP fusion gene in the place of the GFP gene within Ad/GFPDiSTRES, resulting in the Ad/FasL-GFPDiSTRES vector. The gene discussed is FASLG; the disease is prostate carcinoma.